Fig. 2: Clinical trial scheme and demographic and clinical characteristics of the enrolled patients. | Cell Discovery

Fig. 2: Clinical trial scheme and demographic and clinical characteristics of the enrolled patients.

From: Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma

Fig. 2: Clinical trial scheme and demographic and clinical characteristics of the enrolled patients.The alternative text for this image may have been generated using AI.

a The treatment scheme showing the enrolled patients who underwent leukapheresis and then received lympho-depleting chemotherapy. After CAR-T products were successfully manufactured, patients were treated with CAR-T cells. The efficacy and toxicity were monitored during follow-up. b Flow diagram describing numbers of patients enrolled in this clinical trial. Enrollment occurred to obtain peripheral blood for manufacture of the CAR-T products and then the prospective patients were required to meet eligibility to infuse CAR-T cells.

Back to article page